2019
HIV Risk and Prevention Outcomes in a Probability-Based Sample of Gay and Bisexual Men in the United States.
Dodge B, Ford J, Bo N, Tu W, Pachankis J, Herbenick D, Mayer K, Hatzenbuehler ML. HIV Risk and Prevention Outcomes in a Probability-Based Sample of Gay and Bisexual Men in the United States. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2019, 82: 355-361. PMID: 31517706, PMCID: PMC6817401, DOI: 10.1097/qai.0000000000002151.Peer-Reviewed Original ResearchConceptsHIV riskNational HIV/AIDS StrategyUS National HIV/AIDS StrategyPrevention outcomesPrimary health care providersHIV/AIDS StrategyBisexual menHalf of GBMsMajority of HIVUndetectable viral loadPre-exposure prophylaxisHIV-positive GBMRecent male partnersHealth care providersCross-sectional surveySample of gayAntiretroviral treatmentViral loadPrEP usersHIV preventionAIDS StrategyCare providersDaily adherenceGeneral populationHIV
2018
Correlates of Recent HIV Testing Among Transgender Women in Greater Kuala Lumpur, Malaysia
Rutledge R, Morozova O, Gibson BA, Altice FL, Kamarulzaman A, Wickersham JA. Correlates of Recent HIV Testing Among Transgender Women in Greater Kuala Lumpur, Malaysia. LGBT Health 2018, 5: 484-493. PMID: 30481120, PMCID: PMC6306652, DOI: 10.1089/lgbt.2018.0021.Peer-Reviewed Original ResearchConceptsPrimary care providersRecent HIV testingHIV testingTransgender womenLogistic regressionHIV/AIDS StrategyCorrelates of HIVPrevious depression diagnosisJoint United Nations ProgrammeHIV testing historyBehavioral risk factorsMultivariate logistic regressionYears of ageMental health functioningBivariate logistic regressionUnited Nations ProgrammeHIV statusHIV treatmentRisk factorsHIV epidemicDepression diagnosisAIDS StrategyAmphetamine useCare providersPrevention services
2017
The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States
Borre ED, Hyle EP, Paltiel AD, Neilan AM, Sax PE, Freedberg KA, Weinstein MC, Walensky RP. The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States. The Journal Of Infectious Diseases 2017, 216: 798-807. PMID: 29029344, PMCID: PMC5853503, DOI: 10.1093/infdis/jix349.Peer-Reviewed Original ResearchConceptsNational HIV/AIDS StrategyIncremental cost-effectiveness ratioHuman immunodeficiency virusCost-effectiveness ratioUS National HIV/AIDS StrategyHIV/AIDS StrategyAntiretroviral therapy costsSubstantial clinical benefitHigh HIV prevalenceGeneral US populationYears of lifeVirologic suppressionViral suppressionClinical outcomesAdherence interventionsClinical benefitHIV prevalenceHIV transmissionImmunodeficiency virusMSM populationAIDS StrategyTherapy costsTreatment targetsUS populationBlack men
2013
Criminalization of HIV transmission and exposure: research and policy agenda.
Lazzarini Z, Galletly CL, Mykhalovskiy E, Harsono D, O’Keefe E, Singer M, Levine RJ. Criminalization of HIV transmission and exposure: research and policy agenda. American Journal Of Public Health 2013, 103: 1350-3. PMID: 23763428, PMCID: PMC3966663, DOI: 10.2105/ajph.2013.301267.Peer-Reviewed Original ResearchConceptsHIV exposure lawsPolicy agendaPolicy effortsProsecutorial guidelinesPublic health policyFederal fundsUS jurisdictionsHealth policyUS National HIV/AIDS StrategyHIV/AIDS StrategyPublic health systemLaw's effectivenessNational HIV/AIDS StrategyUnited StatesEnforcementAIDS StrategyTransmission of HIVPrevention effortsOpportunity costHealth systemFuture researchLawPotential negative impactHIV incidenceHIV transmission
2012
The cost-effectiveness of rapid HIV testing in substance abuse treatment: Results of a randomized trial
Schackman BR, Metsch LR, Colfax GN, Leff JA, Wong A, Scott CA, Feaster DJ, Gooden L, Matheson T, Haynes LF, Paltiel AD, Walensky RP. The cost-effectiveness of rapid HIV testing in substance abuse treatment: Results of a randomized trial. Drug And Alcohol Dependence 2012, 128: 90-97. PMID: 22971593, PMCID: PMC3546145, DOI: 10.1016/j.drugalcdep.2012.08.009.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsSubstance abuse treatment programsNational HIV/AIDS StrategyCost-effectiveness ratioCommunity-based substance abuse treatment programsUndiagnosed HIV prevalenceRisk reduction counselingRapid HIV testingTreatment programHIV testingHIV prevalenceSite rapid testingSite rapid HIV testingHIV risk reduction counselingHIV/AIDS StrategyIncremental cost-effectiveness ratioHIV testing strategiesLife expectancyHIV testing offerPrior testing historyReceipt of resultsSubstance abuse treatmentRapid testingHIV screeningPatient demographicsU.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008.
Althoff KN, Buchacz K, Hall HI, Zhang J, Hanna DB, Rebeiro P, Gange SJ, Moore RD, Kitahata MM, Gebo KA, Martin J, Justice AC, Horberg MA, Hogg RS, Sterling TR, Cescon A, Klein MB, Thorne JE, Crane HM, Mugavero MJ, Napravnik S, Kirk GD, Jacobson LP, Brooks JT. U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Annals Of Internal Medicine 2012, 157: 325-35. PMID: 22944874, PMCID: PMC3534765, DOI: 10.7326/0003-4819-157-5-201209040-00005.Peer-Reviewed Original ResearchConceptsCD4 cell countCD4 T-lymphocyte cell countMedian CD4 cell countT-lymphocyte cell countAntiretroviral therapy useHIV VLCell countNA-ACCORDHIV RNATherapy useViral loadU.S. National HIV/AIDS StrategyHealth outcomesNational HIV/AIDS StrategyCanadian HIV Trials NetworkHIV/AIDS StrategyActive antiretroviral therapyHIV outpatient clinicAnnual cross-sectional analysesHIV Cohort StudyProportion of participantsNational surveillance systemRelated health outcomesSimilar demographic characteristicsCross-sectional analysis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply